Senti Biosciences Inc

Senti Biosciences, Inc. operates as a biotechnology company. It develops gene circuit technology platforms which enable the development of next-generation cell and gene therapies. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

– Celadon Partners to acquire Senti's manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies –

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

Five presentations showcase the modularity and applicability of Senti's Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages Five presentations showcase the modularity and applicability of Senti's Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 –

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology -

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 –

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS -

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

AACR abstracts highlight the Company's proprietary gene circuit engineered allogeneic CAR-NK cell therapies being developed for hematologic and solid tumors AACR abstracts highlight the Company's proprietary gene circuit engineered allogeneic CAR-NK cell therapies being developed for hematologic and solid tumors

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

BigBear.ai Holdings

DALLAS--(BUSINESS WIRE)--Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection with the following special purpose acquisition companies (“SPACs”): BigBear.ai Holdings, Inc. f/k/a GigCapital4 Inc. (NYSE: BBAI), Senti Biosciences, Inc. f/k/a Dynamics Special Purpose Corp (NASDAQGM: SNTI), Tango Therapeutics, Inc.

Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

NEW YORK--(BUSINESS WIRE)---- $SNTI #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dynamics Special Purpose Corp., which merged with Senti Bioscience, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) on June 8, 2022. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/snti.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that effective on February 1, 2023, the Compensation Committee of Senti Bio's Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company's common stock with a per share exercise price of $1.81. These awards were made under the Company's 2022 Inducement Equity Plan (the Plan).

Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti's Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.

Senti Bio to Present at the SVB Securities Global Biopharma Conference

– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors –

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 5:15 p.m. PT.

Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies –

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML –

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS -

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on October 27, 2022, the compensation committee of Senti Bio's board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company's common stock with a per share exercise price of $2.39. These awards were made under the Company's 2022 Inducement Equity Plan (the Plan).

Senti Bio Announces New Employment Inducement Grants

Innovid Corp

Workhorse Group

While the below market ideas may very well represent the best penny stocks under $3 to buy now, you must realize the dirty little secret. Usually, when publicly traded securities fall this low, it's not for good reasons.

7 Best Penny Stocks Under $3 to Buy Now

Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

American Virtual Cloud Technologies

Here's what you need to know about buying penny stocks on September 29th The post Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today

Mind Medicine MindMed

PolyPid

Biotech penny stocks to watch as stock market crash continues today. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.

Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET.

Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Chardan NexTech Acquisition 2 Corp

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used to support the unique needs of its clients.

News for Senti Biosciences Inc Stock (SNTI)